Relapsed Refractory Follicular Lymphoma clinical trials

Explore recruiting relapsed refractory follicular lymphoma clinical trials.

Recruiting relapsed refractory follicular lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Refractory Follicular Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase II trial investigating MOsunetuzumab and ZAnubrutinib (BGB-3111) in Relapsed/refracTory follicular lymphoma patients (MOZART)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

SYMPHONY-1: A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

Hungary, Belgium, Poland, France, Germany, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma who have Received at least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Netherlands, Greece, Spain, France, Poland, Germany +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma

France, Czechia, Italy, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma

Italy, Spain, Germany, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Lenalidomide with a Non-Randomized, Single Arm US Extension of Mosunetuzumab in Combination with Lenalidomide in Patients with Follicular Lymphoma After at Least One Line of Systemic Therapy

France, Italy, Germany, Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Relapsed Refractory Follicular Lymphoma trials by city

Relapsed Refractory Follicular Lymphoma in Toronto Relapsed Refractory Follicular Lymphoma in Vancouver Relapsed Refractory Follicular Lymphoma in Montreal Relapsed Refractory Follicular Lymphoma in Calgary Relapsed Refractory Follicular Lymphoma in Edmonton Relapsed Refractory Follicular Lymphoma in Ottawa Relapsed Refractory Follicular Lymphoma in Winnipeg Relapsed Refractory Follicular Lymphoma in Quebec City Relapsed Refractory Follicular Lymphoma in Hamilton Relapsed Refractory Follicular Lymphoma in Kitchener Relapsed Refractory Follicular Lymphoma in London Relapsed Refractory Follicular Lymphoma in Halifax Relapsed Refractory Follicular Lymphoma in New York Relapsed Refractory Follicular Lymphoma in Los Angeles Relapsed Refractory Follicular Lymphoma in Chicago Relapsed Refractory Follicular Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease